Microbix Biosystems (TSX:MBX) announced the withdrawal of legal claims, alleging patent infringement, that were filed in Canadian Federal Court against Microbix by ZeptoMetrix in October 2016. The allegations by...
3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) completed the clinical trial component, or Stage 3, of its Hodgkin’s lymphoma (HL) test, known as Telo-HL, and has submitted the data to its statistics consulting partner...
Ortho Regenerative Technologies will begin trading today on the Canadian Securities Exchange under the stock symbol, ORTH. Ortho RTi is an emerging orthopedic and sports medicine technology company with a focus on novel...
Researchers in Australia and the U.S. say they have created a highly elastic surgical glue that can quickly seal even the toughest wounds, without staples or stitches. In a paper published this week in Science...
Theratechnologies (TSX:TH) presented positive 48-week efficacy and safety results at the IDWeek 2017 conference in San Diego for ibalizumab in patients infected with multidrug resistant HIV-1, who completed the 24-week...
Mallinckrodt (NYSE:MNK) has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and...
Titan Pharmaceuticals (NASDAQ:TTNP) and Opiant Pharmaceuticals (NASDAQ:OPNT) are collaborating to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use...
Alcobra (NASDAQ:ADHD) announced plans to merge with closely held Arcturus Therapeutics in an all-stock transaction, creating an RNA-focused company with a 40-60 split in ownership, respectively. Arcturus’ technology...
Mateon Therapeutics (OTCQX:MATN) terminated its Phase 2/3 FOCUS after a third scheduled interim analysis of CA4P in combination with bevacizumab (Avastin) and physician’s choice chemotherapy in patients with platinum...
The FDA has approved Arkis BioSciences’ CerebroFlo external ventricular drain (EVD) catheter that includes Interface Biologics’ Endexo technology. The CerebroFlo catheter has demonstrated a 99% reduction in thrombus...
American CryoStem (OTC:CRYO) has expanded its relationship with Health Innovative Technology (HIT) of Hong Kong. After more than two years as CryoStem’s licensee in Hong Kong, HIT has licensed the patent rights to...
The HydRx Farms subsidiary of Scientus Pharma has received its Access to Cannabis for Medical Purposes Regulations (ACMPR) license from Health Canada. Scientus now is permitted to begin cultivating medicinal cannabis at...
Arbutus Biopharma’s (NASDAQ:ABUS) lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals (NASDAQ:ALNY), announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for...
MaRS Innovation and Evotec AG (FSE:EVT) have launched LAB150, a Toronto-based partnership to tap infrastructure and drug discovery expertise of Evotec and drug discovery projects from the 15-member institutions of MaRS...
Microbix Biosystems (TSX:MBX) has made its first full-scale shipment of antigen, produced using its new bioreactor manufacturing process, following customer validation. Bioreactors offer the prospect for better process...
BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) announced that the board has formed a committee to identify a new chairman with relevant global experience to guide the company through the anticipated upcoming international...
The CBS affiliate in Boston, WBZ-TV, has aired a segment about the opioid crisis, featuring Probuphine, a six-month implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) that releases a steady dose of buprenorphine...
Shares of Opiant Pharmaceuticals were approved for listing on the Nasdaq Capital Market at the opening tomorrow (August 29) under the symbol, OPNT. The company’s common stock had traded on the OTCQB Marketplace since...
An article on Fortune magazine’s web site discusses Titan Pharmaceuticals (NASDAQ:TTNP) and its newest implant with a commonly used Parkinson’s disease drug called ropinirole. Last week, the FDA gave Titan the green...
The FDA has cleared an IND application by Titan Pharmaceuticals (NASDAQ:TTNP) for its ropinirole implant intended to treat the signs and symptoms of Parkinson’s disease. A Phase 1/2 clinical study in patients will...
Aphria (TSX:APH; OTCQB:APHQF) has invested $11.5-million in Scientus Pharma’s HydRx Farms unit by way of a 2-year secured debenture convertible into common shares of Scientus Pharma at a rate of $2.75 a share...
Microbix Biosystems (TSX:MBX) reported record revenue for the fiscal third quarter ended June 30, 2017 of $2.8-million, up 23% from the same quarter a year ago. Net profit was $188,646, compared with $47,953 a year...